| Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA D Gale, ARJ Lawson, K Howarth, M Madi, B Durham, S Smalley, ... PloS one 13 (3), e0194630, 2018 | 166 | 2018 |
| MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical … ME Hegi, E Genbrugge, T Gorlia, R Stupp, MR Gilbert, OL Chinot, ... Clinical Cancer Research 25 (6), 1809-1816, 2019 | 148 | 2019 |
| Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca++-dependent complex of C-reactive protein with very-low–density … CH Toh, J Samis, C Downey, J Walker, L Becker, N Brufatto, L Tejidor, ... Blood, The Journal of the American Society of Hematology 100 (7), 2522-2529, 2002 | 135 | 2002 |
| Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC) B Ricciuti, G Jones, M Severgnini, JV Alessi, G Recondo, M Lawrence, ... Journal for immunotherapy of cancer 9 (3), 2021 | 132 | 2021 |
| Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling V Plagnol, S Woodhouse, K Howarth, S Lensing, M Smith, M Epstein, ... PloS one 13 (3), e0193802, 2018 | 116 | 2018 |
| Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer N Guibert, G Jones, JF Beeler, V Plagnol, C Morris, J Mourlanette, ... Lung Cancer 137, 1-6, 2019 | 100 | 2019 |
| Extent and Patterns of MGMT Promoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres D Sciuscio, AC Diserens, K Van Dommelen, D Martinet, G Jones, ... Clinical Cancer Research 17 (2), 255-266, 2011 | 98 | 2011 |
| High-or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial J van Dorp, C Pipinikas, BBM Suelmann, N Mehra, N van Dijk, G Marsico, ... Nature medicine 29 (3), 588-592, 2023 | 36 | 2023 |
| Dynamic changes in circulating tumor DNA during chemoradiation for locally advanced lung cancer MN Corradetti, JA Torok, AJ Hatch, EP Xanthopoulos, K Lafata, C Jacobs, ... Advances in radiation oncology 4 (4), 748-752, 2019 | 20 | 2019 |
| Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay J Remon, A Swalduz, D Planchard, S Ortiz-Cuaran, L Mezquita, L Lacroix, ... PLoS One 15 (6), e0234302, 2020 | 19 | 2020 |
| Lipoprotein-complexed C-reactive protein and the biphasic transmittance waveform in critically ill patients. M Nesheim, J Samis, J Walker, L Becker, N Brufatto, T Fischer, L Tejidor, ... Blood reviews 16, S15-22, 2002 | 14 | 2002 |
| Early detection of competing resistance mutations using plasma next-generation sequencing (NGS) in patients (pts) with EGFR-mutant NSCLC treated with … NM Guibert, C Paweletz, Y Hu, NB Feeney, V Plagnol, V Poole, G Jones, ... Journal of Clinical Oncology 35 (15_suppl), 11529-11529, 2017 | 11 | 2017 |
| Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study DA Breadner, MD Vincent, R Correa, M Black, A Warner, M Sanatani, ... Lung Cancer 165, 145-151, 2022 | 10 | 2022 |
| High yield of pleural cell-free DNA for diagnosis of oncogenic mutations in lung adenocarcinoma K Mahmood, P Jampani, JM Clarke, S Wolf, X Wang, MM Wahidi, ... Chest 164 (1), 252-261, 2023 | 9 | 2023 |
| Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study F Lynce, C Mainor, RN Donahue, X Geng, G Jones, I Schlam, H Wang, ... Nature communications 15 (1), 2691, 2024 | 7 | 2024 |
| Osimertinib and capmatinib combination therapy to overcome MET Y1003N-mediated resistance in EGFR-mutant NSCLC: a case report M Wilgucki, V Yeung, G Ho, GLB Montenegro, G Jones, JE Reuss, SV Liu, ... JTO Clinical and Research Reports 3 (10), 100396, 2022 | 6 | 2022 |
| Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or … F Lynce Age (mean (SD) 51, 11.54, 2022 | 5 | 2022 |
| Early prediction of outcomes to PD1 inhibitors in non-small cell lung cancer (NSCLC) using next generation sequencing (NGS) of plasma circulating tumor DNA (ctDNA). N Guibert, G Jones, JF Beeler, V Plagnol, M Delaunay, A Casanova, ... Journal of Clinical Oncology 36 (15_suppl), 9078-9078, 2018 | 5 | 2018 |
| Feasibility of an amplicon-based liquid biopsy for ALK and ROS1 fusions in advanced non-small cell lung cancer (NSCLC) patients L Mezquita, Y Hu, K Howarth, C Jovelet, D Planchard, L Lacroix, ... Cancer Research 78 (13_Supplement), 4581-4581, 2018 | 4 | 2018 |
| MGMT methylation testing in RTOG 0525: A phase III trial of newly diagnosed glioblastoma KD Aldape, G Jones, M Wang, M Hegi, RC Janzer, R Stupp, MP Mehta, ... Journal of Clinical Oncology 27 (15_suppl), 2051-2051, 2009 | 4 | 2009 |
